Cymabay Therapeutics, Inc. (NASDAQ:CBAY) is an interesting stock at present. Now trading with a market value of 166.79M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.
Itâ€™s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. Cymabay Therapeutics, Inc. (NASDAQ:CBAY), currently has 13.67 million of cash on the books, which is offset by 2.8 million in current liabilities. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 25.38 million in total assets, balanced by 16.15 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.
Cymabay Therapeutics, Inc. (CBAY) saw -2.2 million in free cash flow last quarter, representing a quarterly net change in cash of 3.18 million. Perhaps most importantly where cash movements are concerned, the company saw about -2.2 million in net operating cash flow.
As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 4.79 million in total revenues. That represents a quarterly year/year change in revenues of 0.00 in sequential terms, the CBAY saw sales decline by 0.00.
But what about the bottom line? After all, that’s what really matters in the end. Cymabay Therapeutics, Inc. (CBAY) is intriguing when broken down to its core data. The cost of selling goods last quarter was 9,000, yielding a gross basic income of 4.78 million. For shareholders, given the total diluted outstanding shares of 26.61 million, this means overall earnings per share of -0.20. Note, this compares with a consensus analyst forecast of -0.25 in earnings per share for its next fiscal quarterly report.
Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.58 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Cymabay Therapeutics, Inc..